Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
News
$ 8.17
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Data is available to registered users only
Target Price
The average target price of VNDA is 14 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Data is available to registered users only
Buy
Sell